Controlling hypertension. A research success story

Archives of Internal Medicine

Volumn 156, Issue 17, 1996, Pages 1926-1935

  Dustan, Harriet P ^a   Roccella, Edward J ^b   Garrison, Howard H ^c,d  

^a UNIVERSITY OF VERMONT   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c Office of Public Affairs   (United States)

^d Federation of American Societies for Experimental Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COSTS AND COST ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; UNITED STATES;

EID: 0029798724     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.17.1926     Document Type: Review

References (67)

1. Bruenn HG. Clinical notes on the illness and death of President Franklin D. Roosevelt. Arch Intern Med. 1970;72:579-591.
2. Messerli FH. This day 50 years ago. N Engl J Med. 1995;332:1038-1039.
3. Janeway TC. A clinical study of hypertensive cardiovascular disease. Arch Intern Med. 1913;12: 755-798.
4. Society of Actuaries. Blood Pressure: Report of the Joint Committee on Mortality of the Association of Life insurance Medical Directors and the Actuarial Society of America. New York, NY: Society of Actuaries; 1925.
5. Society of Actuaries. Blood Pressure Study 1939. New York, NY: Society of Actuaries and Association of Life Insurance Medical Directors; 1940.
6. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge, Mass: Harvard University Press; 1980:257.
7. National Center for Health Statistics. Blood pressure of adults by age and sex: United States 1960-1962. Vital Health Stat. 1964;4:1-16. Ser 11, No. 4.
8. Smithwick RH. Surgery of the autonomic nervous system. N Engl J Med. 1947;236:662-669.
9. Kempner W. Treatment of hypertensive vascular disease with rice diet. Am J Med. 1948;4: 545-577.
10. Page IH, Corcoran AC. Arterial Hypertension: Its Diagnosis and Treatment. Chicago, III: Year Book Medical Publishers Inc; 1949:328-330.
11. Freis ED, Finnerty FA, Schnaper HW, Johnson RL. The treatment of hypertension with hexamethonium. Circulation. 1952;5:20-27.
12. Schroeder HA. The effect of 1-hydrazinophthalazine in hypertension. Circulation. 1952;5:28-37.
13. Reubi FC. Renal hyperemia induced in man by a new phthalazine derivative. Proc Soc Exp Biol Med. 1950;73:102-103.
14. Wilkins RW, Judson WE. Use of Rauwolfia serpentina in hypertensive patients. N Engl J Med. 1953;248:48-53.
15. Vakil RJ. A clinical trial of Rauwoltia serpentina in essential hypertension. Br Heart J. 1949;11: 350-355.
16. Perry HM Jr, Schroeder HA. The effect of treatment on mortality ratio in severe hypertension. Arch Intern Med. 1958;102:418-425.
17. Dustan HP, Schneckloth RE, Corcoran AC, Page IH. The effectiveness of the long term treatment of malignant hypertension. Circulation. 1958;18: 644-651.
18. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, I: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
19. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-1152.
20. National Heart, Blood Vessel, Lung, and Blood Act of 1972. Pub L No. 92-423.
21. Roccella EJ, Burt V, Horan MJ, Cutler J. Changes in hypertension awareness, treatment and control rates: 20 year trend data. Ann Epidemiol. 1993; 3:547-549.
22. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144:1045-1057.
23. Maxwell RA, Eckhardt SB. Drug Discovery: A Case-book and Analysis. Clifton, NJ: Humana Press; 1990.
24. Meldrum NU, Roughlon FJW. Carbonic anhydrase: its preparation and properties. J Physiol. 1933;80:113-142.
25. Strauss MB, Southworth H. Urinary changes due to sulfanilamide administration. Bull Johns Hopkins Hosp. July 1938;63:41-45.
26. Mann T, Keilin D. Sulphanilamide as a specific inhibitor of carbonic anhydrase. Nature. 1940; 146:164-165.
27. Beyer KH Jr. Discovery of the thiazides: where biology and chemistry meet. Perspect Biol Med. 1977;20:410-420.
28. Tapia F, Dustan HP, Schneckloth RE, Corcoran AC, Page IH. Enhanced effectiveness of ganglion blocking agents in hypertensive patients during administration of a saluretic agent (chlorothiazide). Lancet. 1957;2:831-833.
29. Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chorothiazide (Diuril). JAMA. 1958;166:137-140.
30. Oliver G, Schafer EA. The physiological effects of extracts of suprarenal capsules. J Physiol. 1895; 18:230-276.
31. Lewandowsky M. Ueber Schwankungen des Vagusstromes bei Volumänderungen der lunge. Arch Ges Physiol. 1898;73:288-296.
32. Stolz F. Ueber adrenalin und alkylaminoacetobrenzcatechin. Bericht Dtsch Chem Gersel. 1904; 37:4149-4154.
33. Elliott TR. On the action of adrenalin. J Physiol. May 21, 1904;31:20-21.
34. Loewi O. Über humorale übertragbarkeit der Herznervenwirking. Pflugers Arch. 1921;189:239-242.
35. von Euler US. Identification of sympathomimetic ergone in adrenergic nerves of cattle (sympathin N) with laevo-nor-adrenaline. Acta Physiol Scand. 1948;16:63-74.
36. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586-600.
37. Black JW. Ahlquist and the development of beta-adrenoceptor antagonists. Postgrad Med J. 1976; 52(suppl 4):11-13.
38. Gillam PMS, Prichard BN. Use of propranolol in angina pectoris. BMJ. 1965;5457:337-339.
39. Gillam PMS, Prichard BNC. Discovery of the hypotensive effect of propranolol. Postgrad Med J. 1976;52(suppl 4):70-75.
40. Hansteen V. Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation. 1983;67:1-57-1-60.
41. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J Physiol. 1882;4:29.
42. Murad F. Drugs used for the treatment of angina: organic nitrates, calcium channet blockers and β-adrenergic antagonists. In: Gilman AG, Rail TW, Nico AS, Taylor P, eds. Pharmacological Basis of Therapeutics. 8th ed. New York, NY: McGraw-Hill International Book Co; 1993:764-765.
43. Neumann M, Luisada AA. Double blind evaluation of orally administered iproveratril in patients with angina pectoris. Am J Med Sci. 1966; 251:552-556.
44. Fleckenstein A. History of calcium antagonists. Circ Res. 1983;52(suppl 1):3-13.
45. Olivari MT, Bartorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi MD. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979;59:1056-1062.
46. Tigerstedt R, Bergman PG. Niere und Kreislauf. Scand Arch Physiol. 1897-1898;8:233-271.
47. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. J Exp Med. 1934;59:347-379.
48. Page IH, Helmer OM. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator. J Exp Med. 1940;71:29-42.
49. Braun-Menendez E, Fasciolo C, Leloir LF, Munoz M. The substance causing renal hypertension. J Physiol. 1940;98:283-298.
50. Skeggs LT, Kahn JR, Shumway NP. The preparation and function of the hypertensin-converting enzyme. J Exp Med. 1956;103:295-299.
51. Elliott OF, Peart WS. Amino acid sequence in a hypertensin. Nature. 1956;177:527-528.
52. Bumpus FM, Schwarz H, Page IH. Synthesis and pharmacology of the octapeptide angiotonin. Science. 1957;125:886-887.
53. 5-Hypertensins I. Helvet Chim Acta. 1958;41:1273-1286.
54. Rocha e Silva M, Beraldo WT, Rosenfeld G. Bradykinin hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol. 1949; 156:261-273.
55. Ferreira SH. A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol Chemother. 1965;24:163-169.
56. Yang HVT, Erdös EG, Levin Y. A dipeptidyl carboxypepitidese that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta. 1970;214:374-376.
57. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196:441-444.
58. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult United States population: data from the Health Examination Surveys, 1960-1991. Hypertension. 1995;26:60-69.
59. Health, United States, 1993. Hyattsville, Md: National Center for Health Statistics; 1994. Publication PHS 94-1232.
60. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
61. Joint National Committee. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
62. National Institutes of Health, National Heart Lung, and Blood Institute. Morbidity and Mortality 1996: Chartbook on Cardiovascular, Lung, and Blood Diseases: Data Points Document. Bethesda, Md: National Institutes of Health; 1996.
63. Health Promotion and Disease Prevention: United States, 1990. Hyattsville, Md: National Center for Health Statistics; 1993. Publication PHS 93-1513.
64. US Renal Data System USRDS 1993 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1993. Publication USRDS 93-3176.
65. Thom T. The Economic Costs of Cardiovascular Diseases in the United States, 1990. Bethesda, Md: National Heart, Lung, and Blood Institute; 1993.
66. National Institutes of Health, National Heart, Lung, and Blood Institute. Morbidity and Mortality 1996: Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, Md: National Institutes of Health; 1996.
67. Mossinghoff GJ. New Medicines in Development for Heart Disease and Stroke. Washington, DC: Pharmaceutical Research and Manufacturers of America; 1995.